Sage Journals: Discover world-class research

Abstract

Background:

Histone deactylases (HDAC) have a role in the pathogenesis of mycosis fungoides (MF) through their actions on different apoptosis pathways.

Objective:

To assess the possible role played by HDAC-2 in MF by estimating the tissue expression of HDAC2 mRNA in different stages of MF.

Methods:

This study included 28 MF patients and 30 controls. The HDAC-2 levels were detected by real-time polymerase chain reaction (PCR). Correlations of HDAC-2 levels with clinical presentation and different stages of MF were analyzed.

Results:

Mean HDAC-2 level was significantly higher in patients (P < .001) than in controls. HDAC-2 highest mean value was significantly detected in patients with stage IIb, and the lowest mean value was detected in patients with stage Ia (P < .001).

Conclusion:

Up-regulation of tissue HDAC-2 in MF patients might develop a new approach in the understanding of the pathogenesis of MF. Histone deactylases are important targets for molecular cancer therapeutics.

Keywords

apoptosis cancer therapeutics cell cycle HDAC-2 mycosis fungoides

Get full access to this article

View all access options for this article.

References

Wong

. Novel biomarkers, dysregulated epigenetics and therapy in cutaneous T-cell lymphoma. Dicov Med. 2013;16:71-78.

Kouzarides

. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 1999;9:40-48.

Zhang

Fang

Jiao

. The structure and function of histone deacetylases: the target for anti-cancer therapy. Curr Med Chem. 2008;15:2840-2849.

Song

Noh

Lee

. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005;113:264-268.

Pasqualucci

Bereschenko

Niu

. Molecular pathogenesis of non-Hodgkin’s lymphoma: the role of Bcl-6. Leuk. Lymphoma. 2003;44:S5-S12.

Liu

Kuljaca

Tee

Marshall

. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev. 2006;32:157-165.

Nevala

Karenko

Vakeva

Ranki

. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol. 2001;145:928-937.

Winter

Moser

Meunier

. Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis. EMBO J. 2013;32:3176-3191.

Poligone

Lin

Chung

. Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma. Core Evid. 2011;6:1-12.

10.

Olsen

Vonderheid

Pimpinelli

. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713-1722.

11.

Livak

Schmittgen

. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.

12.

Jain

Zain

. Romidepsin in the treatment of cutaneous T-cell lymphoma. Blood Med. 2011;2:37-47.

13.

Jiang

. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol. 2006;3:285-290.

14.

Wagner

Hackanson

Lubbert

Jung

. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics. 2010;1:117-136.

15.

Chang

Lin

Chen

. HDAC2 promotes cell migration/invasion abilities through HIF-1alpha stabilization in human oral squamous cell carcinoma. J Oral Pathol Med. 2011;40:567-575.

16.

Minucci

Pelicci

. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51.

17.

Richon

Garcia-Vargas

Hardwick

. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009;280:201-210.

18.

Kurundkar

Srivastava

Chaudhary

. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Topical Appl Pharmacol. 2013;266:233-244.